Gene therapy CTx1000 enters first human safety trial for ALS
Disease control
Recruiting now
This early-stage study tests a single dose of the gene therapy CTx1000 in 15 people with ALS (Lou Gehrig's disease). The main goal is to see if the treatment is safe and tolerable, not to cure the disease. Participants must have been diagnosed within the last 2 years and be on st…
Phase: PHASE1 • Sponsor: Celosia Therapeutics Pty Ltd • Aim: Disease control
Last updated May 17, 2026 04:01 UTC